AACR 2024 | PSMA imaging pre- and post-177Lu-PSMA-617 treatment in mCRPC

Andres Ricaurte-Fajardo, MD, Weill Cornell Medicine, New York, NY, discusses findings from a Phase I/II trial (NCT04506567) of 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). Patients were given 177Lu-PSMA-617 over two fractionated doses on days 1 and 15 and whilst PSMA analysis of the lesions were not associated with outcomes such as overall survival, it was associated with adverse effects such as fatigue. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.